Denali Therapeutics Announces Initial Public Offering
On December 7, 2017, Denali Therapeutics, a biotech company that develops new molecular therapies for neurodegenerative diseases, announced its initial public offering of 13,888,888 million shares of its Class A common stock at a price to the public of $18 per share, resulting in estimated net proceeds to the company of $250,000,000. The shares began trading on the Nasdaq exchange on December 8, 2017, under the ticker symbol "DNLI." Wilson Sonsini Goodrich & Rosati represented Denali in the offering.
Goldman Sachs & Co. LLC, Morgan Stanley, and J.P. Morgan are acting as joint book-running managers for the offering, and Evercore Group L.L.C. is acting as lead manager for the offering.
For more information, please see Denali's press release.